(Press-News.org) PHILADELPHIA — Researchers have identified two small-molecule inhibitors that effectively targeted the focal adhesion kinase (FAK), an enzyme present in certain cancers that helps tumors thrive and survive.
If the drugs are developed into oral therapeutic agents in the future, they could open up the potential for more effective and less toxic cancer therapies, according to research presented at The American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.
"It is well known that FAK is overexpressed in more than 89 percent of colon cancer tumors, helping these cancer cells survive and spread," said Vita M. Golubovskaya, Ph.D., associate professor in the department of surgical oncology at Roswell Park Cancer Institute, Buffalo, N.Y., and co-founder and senior scientist of CureFAKtor Pharmaceuticals. "We have found that targeting a specific site of FAK, called the autophosphorylation site, is an effective way to kill colon cancers cells, as it blocks FAK activation and its survival signaling."
Through prior research, Golubovskaya and colleagues identified a novel cancer therapy approach that targets the autophosphorylation site of FAK, known as Y397. Once it is "activated" the Y397 site acts as a controller that can "activate" additional cells of the FAK enzyme.
"Thus, our goal was to inhibit this Y397 site to block FAK activity," Golubovskaya said.
To do that, the researchers screened more than 140,000 small molecules from the National Cancer Institute database and identified several small molecules that could effectively target Y397. They then tested all of these molecules and found two that were the most potent at stopping colon cancer-cell growth: Y11 and Y30.
The effect of Y11 and Y30 were then tested on colon cancer cells. Compared with a commercially available inhibitor, Y11 and Y30 decreased the viability of all colon cancer cells in a time- and dose-dependent manner.
"Most companies target a site called the ATP binding site, which is very conservative, thus drugs developed to target this site are less specific and more toxic," Golubovskaya said. "Our inhibitors are very specific, inhibiting colon cancer survival and decreasing its viability and inhibiting tumor formation."
According to Golubovskaya, the next step is to test Y11 and Y30 in mice, eventually conducting pre-clinical studies with the goal in the future to use these drugs in patients after clinical trials.
###
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes 32,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes six major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists, providing a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.
Small-molecule inhibitors effectively targeted active colon cancer enzyme
2010-10-29
ELSE PRESS RELEASES FROM THIS DATE:
Researchers build colony of colon cancer stem cells to test new approach to therapy
2010-10-29
PHILADELPHIA — University of Pittsburgh researchers have devised a three-dimensional system in laboratory culture that mimics the growth patterns of colon cancer stem cells in patients. Their findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.
The assay, which uses green fluorescent "reporter" proteins to watch the process of stem cell differentiation, is designed to understand how these cancer stem cells behave, and to identify and test therapies that could halt production ...
Origin of skillful stone-tool-sharpening method pushed back more than 50,000 years
2010-10-29
A highly skillful and delicate method of sharpening and retouching stone artifacts by prehistoric people appears to have been developed at least 75,000 years ago, more than 50,000 years earlier than previously thought, according to a new study led by the University of Colorado at Boulder.
The new findings show that the technique, known as pressure flaking, took place at Blombos Cave in South Africa during the Middle Stone Age by anatomically modern humans and involved the heating of silcrete -- quartz grains cemented by silica -- used to make tools. Pressure flaking ...
Study says solar systems like ours may be common
2010-10-29
Nearly one in four stars like the sun could have Earth-size planets, according to a University of California, Berkeley, study of nearby solar-mass stars.
UC Berkeley astronomers Andrew Howard and Geoffrey Marcy chose 166 G and K stars within 80 light years of Earth and observed them with the powerful Keck telescope for five years in order to determine the number, mass and orbital distance of any of the stars' planets. The sun is the best known of the G stars, which are yellow, while K-type dwarfs are slightly smaller, orange-red stars.
The researchers found increasing ...
Size of protein aggregates, not abundance, drives spread of prion-based disease
2010-10-29
PROVIDENCE, R.I. [Brown University] — Mad Cow disease and its human variant Creutzfeldt—Jakob disease, which are incurable and fatal, have been on a welcome hiatus from the news for years, but because mammals remain as vulnerable as ever to infectious diseases caused by enigmatic proteins called prions, scientists have taken no respite of their own. In the Oct. 29 edition of the journal Science, researchers at Brown University report a key new insight into how prion proteins — the infectious agents — become transmissible: In yeast at least, it is the size of prion complexes, ...
Kidney transplant numbers increase for elderly patients
2010-10-29
Elderly patients with kidney failure get kidney transplants more often than they did a decade ago, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). The results suggest that the chances of receiving a kidney transplant are better than ever for an older patient who needs one.
Kidney failure afflicts nearly half a million individuals in the United States, and 48% of sufferers are 60 years of age or older. Kidney disease patients who obtain a transplant live longer than those that remain on dialysis. ...
Cancer's hiding spots revealed
2010-10-29
CAMBRIDGE, Mass. -- In a study of mice with lymphoma, MIT biologists have discovered that a small number of cancer cells escape chemotherapy by hiding out in the thymus, an organ where immune cells mature. Within the thymus, the cancer cells are bathed in growth factors that protect them from the drugs' effects. Those cells are likely the source of relapsed tumors, said Michael Hemann, MIT assistant professor of biology, who led the study.
The researchers plan to soon begin tests, in mice, of drugs that interfere with one of those protective factors. Those drugs were ...
In response to chemo, healthy cells shield cancer cells
2010-10-29
Many times, cancer patients respond very well to chemotherapy initially only to have their disease return, sometimes years later. Now researchers reporting in the October 29th issue of the journal Cell, a Cell Press publication, have new insight into the factors that allow some lingering tumor cells to resist treatment and to seed that kind of resurgence.
Contrary to expectations, it appears that the answer doesn't necessarily lie in the cancerous cells themselves. The evidence based on studies of mice with lymphoma shows that cues coming from healthy cells in response ...
Low birth weight may lead to poor growth rate in children with kidney disease
2010-10-29
The lower the birth weight, the greater the chance of poor growth rate in children with chronic kidney disease (CKD), according to a new study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).
In the general population, low birth weight is not an important cause of poor growth and short stature. To determine whether low birth weight is a risk factor for poor growth in children with CKD, Larry Greenbaum, MD, PhD (Emory University and Children's Healthcare of Atlanta, Atlanta, GA) and his colleagues analyzed results from ...
Caltech/JPL experiments improve accuracy of ozone predictions in air-quality models
2010-10-29
PASADENA, Calif.—A team of scientists led by researchers from the California Institute of Technology (Caltech) and NASA's Jet Propulsion Laboratory (JPL) have fully characterized a key chemical reaction that affects the formation of pollutants in smoggy air. The findings suggest that in the most polluted parts of Los Angeles—and on the most polluted days in those areas—current models are underestimating ozone levels, by between 5 to 10 percent.
The results—published in this week's issue of the journal Science—are likely to have "a small but significant impact on the predictions ...
Genetic variants may affect the risk of breast cancer in women with BRCA2 mutations
2010-10-29
NEW YORK, October 28, 2010 – An international study led by researchers at Memorial Sloan-Kettering Cancer Center has identified genetic variants in women with BRCA2 mutations that may increase or decrease their risk of developing breast cancer. The study was published today online in the open-access journal PLoS Genetics.
The findings of the study suggest that genetic variants on chromosomes 10 and 20 may modify risk for breast cancer among women with a BRCA2 mutation.
Researchers analyzed DNA samples from 6,272 women with BRCA2 mutations in a two-stage genome-wide ...